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Summary
AIM OF THE STUDY: In the era of pangenotypic treatment
regimens against hepatitis C virus (HCV) infection, data
from postmarketing observational studies are crucial to
better understand the treatment patterns used in specific
countries and treatment outcomes under real-life condi-
tions. We report data from Switzerland from an ongoing,
multinational postmarketing observational study on the
pangenotypic treatment regimen of glecaprevir (GLE;
NS3/4A protease inhibitor) and pibrentasvir (PIB; NS5A in-
hibitor), coformulated as GLE/PIB.
METHODS: Adults infected with chronic HCV genotypes
1–6 were eligible to participate in the postmarketing ob-
servational study if they started GLE/PIB at the treating
physician’s discretion. The primary objective was to eval-
uate the effectiveness of GLE/PIB based on sustained vi-
rological response 12 weeks after completion of treatment
(SVR12); secondary outcomes included patient-reported
outcomes (Fatigue Severity Scale, Work Productivity and
Activity Impairment Questionnaire, Pictorial Representa-
tion of Illness and Self Measure tool) and safety data.
RESULTS: In Switzerland, 109 patients were enrolled,
and 107 patients received ≥1 dose GLE/PIB (94.4% non-
cirrhotic; 43.9%/14.0%/29.0%/13.1% GT1/GT2/GT3/GT4;
89.7% treatment-naïve; 91.6% assigned to an 8-week
GLE/PIB regimen). Overall, 95 of 98 patients with suffi-
cient follow-up data (96.9%) achieved SVR12 (95% con-
fidence interval [CI] 91.4% to 99.0%), and 91.6% in the
safety population (including six non-virological failures).
The three treatment failures were due to relapse. All three
failures were GT3, without cirrhosis and treatment naïve.
Patient-reported outcomes improved as well. GLE/PIB
was well tolerated with no serious adverse events and no
adverse events leading to discontinuation or interruption of
GLE/PIB treatment.
CONCLUSION: These real-world effectiveness and safety
data of GLE/PIB in patients from Switzerland were con-
sistent with those seen in the multinational registration
trials. (Trial registration number: Clinicaltrials.gov:
NCT03303599.)
Keywords: chronic hepatitis C, glecaprevir/pibrentasvir,
observational study, real-world, Switzerland
Introduction
Hepatitis C virus (HCV) infection is one of the main caus-
es of chronic liver disease worldwide and 71 million peo-
ple are expected to be chronically infected with HCV (1%
of the global population) [1, 2]. Among the general popula-
tion in Switzerland, the estimated anti-HCV prevalence is
0.7%. The most relevant high-risk groups for acquiring and
spreading the disease are people who use drugs (PWUD),
professional sex workers, prison inmates, migrant popula-
tions, children of infected mothers and men who have sex
with men, and these risk groups have a much higher HCV
prevalence with up to 45% for people who inject drugs [3].
Successful treatment cures the HCV infection, avoids fur-
ther transmission and significantly reduces HCV-related
complications, liver transplantations or death. HCV cure
equates to sustained virological response (SVR), usually
defined as “no HCV RNA detectable” at 12 weeks after
treatment completion (SVR12) [4].
In clinical trials, direct-acting antiviral (DAA) treatments
have achieved SVR12 rates of >90% across all HCV geno-
types [4–8]. The development of the fixed dose combina-
tion of glecaprevir (GLE; NS3/4A protease inhibitor) and
pibrentasvir (PIB; NS5A inhibitor) (GLE/PIB), allowed
for the first time an abbreviated, 8-week treatment course
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for all treatment-naïve, non-cirrhotic patients, which
marked a major step to simplifying HCV treatment algo-
rithms. GLE/PIB demonstrated high virological efficacy in
both treatment-naïve and previously treated patients across
all genotypes [5–8]. Based on a pooled analysis of nine
different phase II and phase III trials, 99.1% of non-cir-
rhotic patients across all HCV genotypes achieved SVR12
following 8 weeks of GLE/PIB treatment (12-week treat-
ment: 99.6%), excluding patients with non-virological fail-
ure (core population with sufficient follow-up data [CPS-
FU] population) [7].
Now that effective and convenient pangenotypic treatment
options are available, the World Health Organization aims
to target the elimination of viral hepatitis (including HCV)
as a public threat by 2030 (new infections reduced by 80%,
mortality reduced by 65%) [1]. To achieve this goal, it is
necessary to decrease viral transmission, reach the popu-
lations at the highest risk for transmission and infection,
and ensure that patients are engaged in care and treatment.
Right now, there is significant heterogeneity in DAA ac-
cess and the types of patients treated across different geo-
graphical regions. Data from multinational postmarketing
observational studies are crucial to a better understanding
of the current, real-world HCV treatment patterns, health-
care resource utilisation, and treatment outcomes in differ-
ent countries as well as in subpopulations underrepresent-
ed in clinical trials, such as elderly patients or people who
use drugs.
In Switzerland, more people die every year from sequelae
of HCV infection than from human immunodeficiency
virus (HIV) infection [9]. Between 2012 and 2017, five
times more deaths were caused by hepatitis C than by HIV
[10]. Approximately 36,000 to 43,000 individuals are cur-
rently infected with chronic HCV [10], with an incidence
of 50 new HCV cases per year [11]. Approximately 30% of
all HCV-infected individuals in Switzerland are not aware
of their HCV infection and therefore cannot benefit from
the new, highly potent DAA regimens such as GLE/PIB
[3]. To date, the available real-world data on DAA treat-
ment in Switzerland are very limited.
We report the first real-world data for GLE/PIB from
Switzerland, generated from a multinational postmarketing
observational study that evaluated the effectiveness and
safety of GLE/PIB in daily clinical routine. We report
SVR12, adverse events, healthcare resource utilisation and
patient-reported outcomes including burden of illness as
assessed with the Pictorial Representation of Illness and
Self Measure (PRISM) tool for 107 HCV patients treated
with GLE/PIB (104 treated according to local labelling).
The same parameters will be reported overall and for rel-
evant subgroups (e.g., PWUD, treatment-naïve and treat-




This prospective, multi-centre, multinational, non-inter-
ventional postmarketing observational study was designed
to evaluate the effectiveness and safety of the GLE/PIB
regimen in patients with chronic HCV infection under real-
world conditions and in a broad patient population as ob-
served in real-world practice (ClinTrial.gov:
NCT03303599). The study was performed in compliance
with Swiss laws and regulations. The study was reviewed
and approved by the responsible Swiss Ethics Committees,
and was conducted in compliance with Swiss legislation.
HCV treatment-naïve or -experienced adults with con-
firmed chronic HCV infection of any genotype, with or
without compensated cirrhosis, were eligible for participa-
tion in this trial, if they planned to start treatment with the
GLE/PIB regimen according to standard of care, in line
with the current local labelling. Treatment decisions were
entirely at the discretion of the treating physician, based on
the clinical characteristics of individual patients. The deci-
sion to initiate the GLE/PIB regimen was made indepen-
dently from this study and preceded the decision to offer
participation in the study. Patients were eligible for enrol-
ment up to 4 weeks after treatment initiation.
The primary objective of the study was to describe the ef-
fectiveness of GLE/PIB, as evidenced by SVR12, overall
and in the following subpopulations of interest: HCV
genotype 1 to 6, cirrhotic or non-cirrhotic (investigator as-
sessment), HCV treatment-experienced or -naïve, elderly
or non-elderly (≥65 or <65 years), and former or current il-
licit drug users (PWUD [people who use [illicit] drugs]) or
non-PWUD.
Secondary outcomes addressed in this publication include:
clinical practice use of GLE/PIB regimen, adherence to
the prescribed GLE/PIB regimen, comorbidities, concomi-
tant medications, treatment tolerability and several patient-
reported outcomes. Patient-reported outcomes included
changes in fatigue, work productivity and disease burden.
In this study, 100 patients were planned to be enrolled.
Here, we present data for 109 patients enrolled between
March and December 2018 at six different sites in Switzer-
land.
Treatment
All participants received GLE/PIB treatment at the physi-
cian’s discretion. The recommended dosage (per Swiss
prescribing information) is 300 mg GLE and 120 mg PIB
once daily for either 8 weeks (non-cirrhotic, treatment-
naïve patients), 12 weeks (all cirrhotic patients), or 16
weeks (pretreated patients with HCV genotype GT3 infec-
tion) [12].
Assessments and outcomes
Demographic, clinical, virological, patient reported out-
comes, healthcare resource utilisation and safety data, as
well as the actual regimen and any concomitant medica-
tions were collected. Visits, procedures and diagnostic
methods were in accordance with the physicians’ routine
clinical practice. Based on the anticipated regular follow
up for patients undergoing HCV treatment, three main vis-
its were recommended for each patient: baseline (within 4
weeks after initiation of GLE/PIB), end of treatment (week
8, 12 or 16, depending on the regimen), and 12 weeks after
treatment completion (SVR12 assessment). Additional vis-
its during and after treatment occurred as scheduled by the
investigator.
HCV RNA tests, using a sensitive polymerase chain reac-
tion test with a lower limit of quantification <50 IU/ml,
were expected to be performed at each visit. The prima-
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ry outcome, SVR12, was defined as HCV RNA below the
lower limit of quantification at 12 weeks (allowed interval:
70 to 126 days) after the last actual dose of GLE/PIB.
Adverse events were collected at each post-baseline visit;
healthcare resource utilisation and concomitant medica-
tions were collected at each visit. Adverse events were
coded using the Medical Dictionary for Regulatory Activ-
ities (MedDRA; Version 21.1). Laboratory data were as-
sessed as per routine practice and changes in key hepatic
parameters (e.g., alanine aminotransferase [ALT], biliru-
bin, etc.) were assessed. Healthcare resource utilisation
was assessed for each patient based on the total number of
face-to-face visits and the total number of telephone calls
with a healthcare provider or designee in relation to the
HCV infection. The study protocol recommended five vis-
its per patient regardless of treatment duration: (1) base-
line, (2) during treatment, (3) end of treatment, (4) early
post-treatment, and (5) the visit to assess sustained viro-
logical response at post-treatment week 12 (SVR12). The
number of visits was at the provider’s discretion based on
routine clinical practice.
Patient-reported outcomes were collected at each main vis-
it and included the PRISM tool, the Fatigue Severity Scale
(FSS), and the Work Productivity and Activity Impairment
(WPAI) Questionnaire. The PRISM tool provides a brief
method to quantify the perceived burden of suffering due
to illness. The tool consists of an A4-size metal board,
which stands for the patient’s life. A yellow disk, repre-
senting the patient, is fixed at the bottom right-hand corner.
The patient is asked to reflect the importance of the illness
in his/her life by placing a red disk, which represents the
illness, on the board. Thereby, the PRISM tools provides a
graphic representation of the patient’s illness in relation to
the patient. The distance between the centre of the yellow
“self” and the red “illness” disk (in cm) is called “self-ill-
ness separation”, and can range from 0 to 27 cm (greater
distance indicates less burden of illness). The validity and
reliability of the PRISM tool have been assessed in more
than 700 patients with various physical illnesses [13].
The WPAI questionnaire is a six-item scale instrument to
measure work absenteeism and presenteeism, and daily
activity impairment. Respondents are asked about time
missed from work and time at work with reduced pro-
ductivity during the last 7 days. The WPAI can easily be
adopted for specific health problems (WPAI-SHP), its use
has been validated in numerous diseases, and WPAI-SHP
has been used in HCV studies [14, 15]. For this study, the
HCV-specific version of the WPAI-SHP, WPAI HepC Ver-
sion 2.0, was [15]. Results are expressed as % absenteeism
(percentage of work time missed due to HCV), % presen-
teeism (percentage of impairment while working due to
HCV), % overall work impairment due to HCV and % gen-
eral activity impairment due to HCV.
The FSS is a nine-item scale which measures the severity
of fatigue and its effect on a person’s activities and
lifestyle. Each item is rated from 1 (completely disagree) to
7 (completely agree), and the FSS total score ranges from
1 (no fatigue) to 7 (very severe fatigue). The scale has been
validated for use in patients with chronic HCV, and an in-
crease of ≥0.7 in mean FSS scores can be considered as a
clinically important difference [16].
Statistical methods
Analysis populations: Effectiveness, healthcare resource
utilisation and patient-reported outcomes were evaluated
for all patients who started the treatment regimen as rec-
ommended for their disease characteristics (core popula-
tion) and who had sufficient follow-up. The primary analy-
sis (SVR12) included all patients of the core population
who had evaluable HCV RNA values ≥70 days after the
last actual dose or whose ≥70 day HCV RNA values were
missing for efficacy or safety reasons, i.e., patients with
HCV RNA values ≥50 IU/ml at the last available mea-
surement, and patients who discontinued the study due to
adverse events (CPSFU population). Safety data were as-
sessed for all patients who received at least one dose of
GLE/PIB (safety population) (see fig. 1 below).
All analyses were mainly descriptive. For the primary
SVR12 outcome and for secondary outcomes of treatment
response (relapse rate), 95% confidence intervals (CIs;
Wilson’s score method) were provided, for both the overall
population and the main subgroups of interest. For patient-
reported outcome scores, means and standard deviations
(SDs) were provided for the changes from baseline to end




A total of 109 patients from Switzerland with chronic HCV
infection were enrolled. Of these, 107 received at least one
dose of GLE/PIB, 104 started the regimen as recommend-
ed for their disease characteristics (core population) and 98
were evaluable for SVR12 (fig. 1). Mean treatment adher-
ence (patient-reported % of prescribed tablets taken) was
≥99% for all patients with data available (n = 107; range
88% to 100%).
Figure 1: Patient disposition.† Consent withdrawn (1 patient), lost
to follow-up after baseline visit (1 patient).‡ Treatment-naïve and
non-cirrhotic patients treated for 12 weeks (2 patients), received
previous direct-acting antiviral treatment (1 patient).GLE = gle-
caprevir; CPSFU = core population with sufficient follow-up data; N
= number of patients; PIB = pibrentasvir; SVR12 = sustained viro-
logical response 12 weeks after completion of treatment.
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Baseline characteristics for the safety population (n = 107)
are summarised in table 1 (additional details can be found
in supplementary tables S1 to S3 in appendix 1, available
online). Most patients were non-cirrhotic (94.4%) and
HCV treatment naïve (89.7%). The few patients with prior
HCV treatment (n = 11) had mostly received interferon-
based therapies (n = 10). GT1 was the most common HCV
genotype (43.9%), followed by GT3 (29.0%), GT2
(14.0%) and GT4 (13.1%); there were no GT5 or GT6 pa-
tients enrolled. Prior or current use of illicit drugs was re-
ported by 55.9% of all patients. Most patients had either
normal renal function (47.3%) or minor renal impairment
(49.5%). Only three patients with moderate, but none with
severe, renal impairment were enrolled (table 1); no patient
had received dialysis treatment. Overall, 17.8% of the pa-
tients had a history of depression or suicide attempts /
self-injury (table S4). The most frequent medical histories
included depression (10.3%), hypertension (9.3%), and
substance dependence (4.7%) (table S5). Most frequently
reported concomitant drugs included methadone (8.4%),
acetylsalicylic acid (8.4%), mefenamic acid (7.5%) and
amlodipine (5.6%) (table S6). Baseline characteristics for
the different HCV genotype subgroups were generally sim-
ilar (table S7).
In line with the recommended treatment regimen for their
disease characteristics, 91.6% of all patients were assigned
to the 8-week GLE/PIB regimen.
Clinical effectiveness
Of 98 patients evaluable for SVR12 (CPSFU population),
95 (96.9%) achieved SVR12 (95% CI 91.4% to 99.0%).
The three failures were due to relapse and all had a GT3
infection. All three patients were treatment-naïve, two of
them were current or former PWUDs (table 2, fig. 2). All
three patients were reported to be treatment-adherent. Of
the 104 patients that started the regimen as recommended
for their disease characteristics (core population), 6 were
lost to follow up.
Healthcare resource utilisation
Healthcare resource utilisation data were available for 100
patients overall. These patients required a median of 4
face-to-face contacts (range 3–8) with healthcare profes-
sionals during the study, including any office visits, emer-
gency room visits or hospitalisations. No additional tele-
phone contacts were required. The small sample of
cirrhotic patients (n = 6) tended to require more visits (me-
dian 6, range 4–7) than the non-cirrhotic group (n = 94,
median 4, range 3–8).
Patient-reported outcomes
Burden of illness data, as assessed with the PRISM tool,
were available for 102 patients at baseline and for 92 pa-
tients at the final visit 12 weeks after treatment completion.
For these patients, the perceived burden of illness de-
creased during GLE/PIB treatment and was maintained at
the final visit at 12 weeks after treatment completion, as
shown by the mean increase of self-illness separation by
4.9 cm (SD 9.7 cm) from baseline to final visit (table 3).
Correspondingly, patients’ work productivity and general
activity improved, as indicated by the WPAI data (table 3).
The mean percentages for overall work impairment, gen-
Table 1: Baseline characteristics (safety population, N = 107).
Variable, number (N) with data
Age (years)
Mean (SD) 52.4 (12.8)
<65 years, n (%) 91 (85.0)




BMI (kg/m2), N = 45*
Mean (SD) 24.5 (5.0)





Viral load (HCV RNA), log10 IU/ml
<6 45 (42.1)
≥6 to <6.3 21 (19.6)
>6.3 39 (36.4)
Unknown 2 (1.9)
Cirrhosis status, n (%)
Non-cirrhotic 101 (94.4)
Cirrhotic 6 (5.6)
Liver fibrosis stage‡, n (%)





HCV pretreatment status, n (%)
Naïve 96 (89.7)
Experienced§ 11 (10.3)
Years since diagnosis of HCV infection, N = 105*
Mean (SD) 14.6 (10.5)
Illicit drug use, n (%), N = 102*
No 45 (44.1)
Yes, at any time 57 (55.9)
Current 15 (14.7)
<6 months ago 3 (2.9)
6 to 12 months ago 1 (1.0)











Respiratory (inhalation) 13 (12.7)
Nasal 9 (8.8)
Oral 1 (1.0)
Patients on stable opiate substitution, n (%), N =
99*
12 (12.1)
Renal function (GFR), n (%), N = 91*
Normal (≥90 ml/min) 43 (47.3)
Mild impairment (≥60 to <90 ml/min) 45 (49.5)
Moderate impairment (≥30 to <60 ml/min) 3 (3.3)
Severe impairment (<30 ml/min) 0
Mode of HCV infection, n (%)
Contaminated needle or IV drug use (current/past) 49 (45.8)
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Variable, number (N) with data
Blood product transfusion 16 (15.0)
Contact with infected individual (other than vertical
transmission)
5 (4.7)
Vertical transmission (mother to child) 3 (2.8)
Occupational exposure 4 (3.7)
Unknown 30 (28.0)
Perceived burden of illness (PRISM tool), N = 102*
Mean SIS (cm) 17.2
Work Productivity and Activity Impairment (WPAI)*
% overall work impairment due to HCV, mean, N =
49
14.0
% general activity impairment due to HCV, mean, N
= 102
18.6
% absenteeism, mean, N = 49 6.4
% presenteeism, mean, N = 47 7.9
Fatigue (FSS), N = 34*
Mean total score 3.7
BMI = body mass index; FSS = Fatigue Severity Scale; GFR = glomeru-
lar filtration rate; GT = HCV genotype; HCV = hepatitis C virus; IU =
international units; IV = intravenous; N = number of patients with data;
n = number of patients with criterion; PRISM = Pictorial Representation
of Illness and Self Measure; SD = standard deviation; SIS = self-illness
separation; WPAI = Work Productivity and Activity Impairment (WPAI
Hep C = Version 2.0) † There were no GT5 or GT6 patients in the Swiss
cohort. ‡ Fibrosis stage was determined by fibroscan (60 patients) or
biopsy (9 patients). § Includes treatment with interferon or pegylated
interferon, with or without ribavirin, or sofosbuvir plus ribavirin with or
without pegylated interferon. * Data were not available from all 107 pa-
tients.
Table 2: Overview of treatment effectiveness of GLE/PIB in the Swiss
cohort.
SVR12 rates (%), overall and by HCV genotype
Overall (N = 98, CPSFU population) 96.9
(95% CI 91.4% to
99.0%)
GT1 (N = 45) 100.0
GT2–4 (N = 53)† 94.3
Supporting information
Patients with relapse, n 3‡
Patients with virological failure on-treatment,
n
0
Patients with early discontinuation of GLE/
PIB, n
0
CI = confidence interval; GLE = glecaprevir; GT = HCV genotype; HCV
= hepatitis C virus; CPSFU = core population with sufficient follow-up
data; PIB = pibrentasvir; PWUD = people who use drugs; SVR12 = sus-
tained virological response 12 weeks after completion of treatment †
There were no GT5 or GT6 patients. ‡ The 3 failures were due to re-
lapse; all were GT3, without cirrhosis and treatment naïve; 2 were cur-
rent or former PWUD.
eral activity impairment, and absenteeism at work had all
decreased by 5–7% at the end of treatment. The general ac-
tivity impairment had continued to improve at 12 weeks af-
ter treatment completion, with an approximate 50% overall
reduction in impairment (% impairment: 18.6% at baseline
and 9.8% at 12 weeks after treatment completion).
Fatigue data, as assessed with the FSS, were available for
34 patients at baseline and for 31 patients at the final visit
12 weeks after treatment completion. Although this num-
ber is low, a mean decrease (improvement) of the FSS total
score of 0.8 points at 12 weeks after treatment completion
was observed. This was above the limit for clinical signif-
icance (decrease ≥0.7 points). Overall, 45.2% of patients
(95% CI 27.6% to 62.7%) achieved a clinically meaning-
ful improvement of ≥0.7 points at the end of treatment, and
54.8% of patients (95% CI 37.3% to 72.4%) still showed
the clinically meaningful improvement at 12 weeks after
treatment completion (table 3).
Safety data
Overall, GLE/PIB treatment was well tolerated in the real-
life setting; there were no serious adverse events and no
adverse events leading to discontinuation or interruption
Figure 2: SVR12 rates (95% CIs as error bars) after treatment
with GLE/PIB in relevant subgroups.
Table 3: Summary of patient-reported outcomes (patients with data
only).
Baseline End of Tx SVR12
visit
Perceived burden of illness (PRISM tool)
Number with data 102 87 92
Mean SIS (cm) 17.2 20.3 21.7
Mean (SD) change from baseline NA 3.4 (7.1) 4.9 (9.7)
Work Productivity and Activity Impairment (WPAI)
% overall work impairment due to HCV
Number with data 49 36 37
Mean percentage 14.0 8.7 11.9




% general activity impairment due to HCV
Number with data 102 88 92
Mean percentage 18.6 13.4 9.8





Number with data 49 36 37
Mean percentage 6.4 3.2 2.7





Number with data 47 34 35
Mean percentage 7.9 5.9 7.7
Mean (SD) change from baseline NA −1.5 (6.6) 0.6 (14.1)
Fatigue Severity Scale (FSS) total score
Number with data 34 31 31
Mean score 3.7 3.1 2.9
Mean (SD) change from baseline NA −0.6 (1.1) −0.8 (1.3)
Improved ≥0.7 points from base-
line, n (%)
NA 14 (45.2) 17 (54.8)
HCV = hepatitis C virus; NA = not applicable; PRISM = Pictorial Rep-
resentation of Illness and Self Measure; SD = standard deviation; SIS
= self-illness separation; SVR12 = sustained virological response 12
weeks after completion of treatment; Tx = treatment FSS: Total score
ranges from 1 (no fatigue) to 7 (very severe fatigue). PRISM tool: SIS
can range from 0 to 27 cm, greater distance indicates less burden of
illness.
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of GLE/PIB treatment (table 4). Fatigue, dyspepsia,
headache, and nausea were the only adverse events occur-
ring in more than one patient.
There was no incidence of drug-induced liver injury: Over-
all, 3 of the 98 patients with liver function laboratory data
available (3.1%) had postbaseline increases of total biliru-
bin to ≥2 times the upper limit of normal, no patient experi-
enced ALT increases of >3 times the upper limit of normal.
Gastrointestinal adverse events (dyspepsia, nausea, diar-
rhoea, constipation, abdominal pain) were reported in 7 pa-
tients (6.5%) overall.
Discussion
This postmarketing observational study on the use of GLE/
PIB for the treatment of chronic HCV infections provides
the first real-world data from Switzerland in a broad pa-
tient population with different concomitant conditions
(supplementary tables S4 and S5 in appendix 1), as ob-
served in routine practice. In this cohort from Switzerland,
GLE/PIB treatment (an 8-week short regimen used in
>90% of cases) yielded SVR12 rates of 96.9% in 98 pa-
tients evaluable for SVR12 (CPSFU population) and of
91.6% in the safety population, including 6 non-virological
failures). This rate is similar to the 98% SVR12 rate iden-
tified in an integrated analysis of phase III studies for pa-
tients receiving the 8-week regimen [7]. The majority of
patients had infections with HCV genotypes GT1 (43.9%)
and GT3 (29.0%), closely reflecting the known worldwide
distribution of HCV genotypes (44% and 25%, respective-
ly) [17]. In this Swiss cohort, there were only three treat-
ment failures due to relapse. All three patients had a GT3
infection, were non-cirrhotic and treatment naïve. Two of
them were current or former PWUDs.
GT3 infections have emerged as the HCV genotype most
difficult to treat in the era of DAAs [4]. The GLE/PIB com-
bination is one of the DAA-based regimens recommend-
ed by the European Association and the Swiss Association
for the Study of the Liver (EASL, SASL) for the treatment
of any HCV genotype in non-cirrhotic patients [4, 18]. As
for any other genotype, a treatment duration of 8 weeks for
GLE/PIB is recommended for treatment-naïve GT3 non-
cirrhotic patients [4, 18]. For the more problematic, treat-
ment-experienced non-cirrhotic patients with GT3 infec-
tion, longer treatment durations of 12 weeks (EASL) [4] or
16 weeks (SASL expert statement [18], in alignment with
the Swiss label [12]) are recommended. The fact, that GT3
Table 4: Summary of adverse event data (safety population).
Adverse event category Number of patients (%)
N = 107
Any adverse event 22 (20.6)
Possibly related (investigator assessment) 12 (11.2)
Serious adverse event 0
Adverse event leading to treatment discon-
tinuation
0
Fatal adverse event 0





Only treatment-emergent adverse events reported.
remains the most difficult to treat HCV genotype is further
reflected by the recommendation to either prolong treat-
ment duration and/or add ribavirin when using other DAAs
[19].
Real-world data for GLE/PIB are also available from other
countries; results were consistent with the results from
Switzerland. From the NAVIGATORE-Lombardia net-
work in Italy, data are available for 723 patients (49% GT1,
10% GT3; 89% treated with the 8-week regimen). In the
Italian cohort, GLE/PIB treatment resulted in an overall
SVR12 rates of 99.3% in the per protocol analysis and
94% in the intention-to-treat analysis. A total of five treat-
ment failures due to relapse were documented [20]. From
the German Hepatitis C registry, prospective data are avail-
able for 552 patients (53% GT1, 33% GT3). Similar to
the Swiss cohort, the majority of patients were treatment-
naïve, had no cirrhosis and received the 8-week GLE/PIB
regimen. The overall SVR12 rate in the German cohort
was 96.7%, with one documented virological failure (re-
lapse) and two documented HCV reinfections [21].
The high SVR12 rates observed in the Swiss cohort were
accompanied by a decrease in burden of illness (PRISM
tool), and improvements in work productivity and general
activity (WPAI), as well as in fatigue (FSS). Improved FSS
outcomes were also observed in the multi-country inter-
im analysis of the same study, which included 720 pa-
tients (data pooled from six countries). Mean FSS scores
decreased by 0.7 (Swiss cohort: decrease by 0.8; table 3),
and 43.6% of patients showed a clinically meaningful im-
provement in fatigue from baseline to SVR12 visit [22].
GLE/PIB real-world treatment was well tolerated in the
Swiss cohort. Overall, 20.6% of patients reported ≥1 ad-
verse event, but there were no serious adverse events and
no adverse events leading to discontinuation or interrup-
tion of GLE/PIB treatment. Safety data from the other real-
world studies performed in Italy, Germany, and Japan had
similar results. In the Italian study, mild adverse events
were reported in 8.3% of the 723 patients treated; 0.7%
of patients documented premature discontinuation of GLE/
PIB [20]. In the study from Germany, 26% of patients re-
ported ≥1 adverse event, 2% of patients had serious ad-
verse events (nine AEs), and <1% of patients (two cases)
had adverse events leading to discontinuation of GLE/PIB
[21]. As known for real-world studies, the adverse event
rates were generally lower when compared with clinical
trials, where adverse event rates of 63% and 68% were re-
ported for the 8- and 12-week regimens, respectively [7].
Fatigue was the most common adverse event (5 patients,
4.7%) in the Swiss cohort. Other adverse events reported
more than once were dyspepsia, headache, and nausea.
Headache and fatigue were also the most commonly ad-
verse events reported in clinical trials [6, 7]. In the Swiss
cohort, only three isolated cases of total bilirubin increases
to ≥2 times the upper limit of normal, and importantly no
ALT increases ≥3 times the upper limit of normal were ob-
served. This is consistent with the integrated safety analy-
sis of phase III data, which identified no incidence of drug-
induced liver injury and a low rate (0.3%) of grade 3 total
bilirubin increases (i.e., >3 times the upper limit of nor-
mal) [7]. Gastrointestinal adverse events were observed in
6.5% of patients, similar to the integrated analysis (6% of
patients with diarrhoea) [7].
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The main limitation of this study is the small sample size
of the Swiss cohort (safety population: n = 107, evaluable
for SVR12: n = 98), and the fact that many subgroups of
interest were too small for valid subgroup analyses of ef-
fectiveness and safety, in particular cirrhotic patients (n =
6), patients with moderate or severe renal impairment (n =
3), or elderly patients (n = 16). However, such subgroup
analyses may become available in the future, based on the
results for the overall population of the ongoing multina-
tional real-world study.
Overall, the first real-world evidence data of GLE/PIB
were consistent with those from the large phase III trials, as
well as with real-life data obtained in other countries (i.e.,
multi-country interim analysis and other postmarketing ob-
servational studies from Italy and Germany), indicating ro-
bust effectiveness and good tolerability of GLE/PIB across
a wide range of different patient populations.
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Appendix 1 Supplementary tables
Table S1: Additional baseline demographic characteristics (safety population, N = 107).
Variable Number (%) of patients
Ethnicity Not Hispanic or Latino 102 (95.3)
Hispanic or Latino 5 (4.7)
Race White 102 (95.3)
Asian 3 (2.8)
Black or African American 2 (1.9)
Current occupational status Employed, full-time 49 (45.8)
Retired 17 (15.9)
Unemployed 17 (15.9)




Highest level of education obtained Low level 18 (16.8)
Medium level 64 (59.8)
High level 13 (12.1)
Unknown 12 (11.2)








Table S2: Additional disease characteristics (safety population, N = 107).
Variable Number (%) of patients
Cirrhotic (Child Pugh classification 5 to 6) 6 (5.6)
APRI <0.5 58 (54.2)
≥0.5 to ≤1 24 (22.4)
>1 16 (15.0)
Unknown 9 (8.4)
APRI = AST to platelet ratio index; AST = aspartate aminotransferase
Table S3: Baseline laboratory data (safety population, N = 107).
Variable Number with data Mean (SD)
HCV RNA level (IU/ml) 105 2,901,194.3 (4,314,763.7)
Log10 IU/ml 105 6.0 (0.87)
ALT (U/l 102 81.2 (63.15)
ALT (ratio) 102 1.8 (1.54)
AST (U/l) 101 61.2 (54.17)
AST (ratio) 101 1.5 (1.42)
Fibrosis-4 98 1.8 (1.69)
GGT (U/l) 98 84.8 (109.62)
Total bilirubin (µmol/l) 97 11.5 (5.22)
Albumin (g/l) 97 39.9 (5.05)
Creatinine (µmol/l) 91 73.8 (16.31)
AFP (ng/ml) 32 5.0 (5.82)
Haemoglobin (g/l) 102 144.1 (16.89)
Platelets (cells × 109/l) 101 227.2 (61.83)
ALT = alanine aminotransferase; AST = aspartate aminotransferase; GGT = gamma-glutamyltransferase; AFP = alpha-fetoprotein
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Table S4: Viral coinfections and solicited comorbidities (safety population, N = 107).
Viral coinfection or solicited comorbidity Number (%) of patients
Viral coinfection HBV 0
HIV 0
History of depression or suicide/self-injury 19 (17.8)
History of cardiovascular disease 16 (15.0)
History of depression or bipolar disorder 11 (10.3)
History of bleeding disorder 6 (5.6)
History of diabetes 3 (2.8)
Transplant history Liver 0
Renal 0
Other 0
Dialysis treatment required 0
Hepatocellular carcinoma 0
HBV = hepatitis B virus: HIV = human immunodeficiency virus
Table S5: Most frequently reported medical histories (≥2% of patients) (safety population, N = 107).
Medical history (MedDRA preferred term) Number (%) of patients
Depression 11 (10.3)
Hypertension 10 (9.3)




Vitamin D deficiency 4 (3.7)
Drug dependence 3 (2.8)
Gall bladder polyp 3 (2.8)
Breast cancer 3 (2.8)
Hepatitis B 3 (2.8)
Migraine 3 (2.8)
Obesity 3 (2.8)
MedDRA = Medical Dictionary for Regulatory Activities
Table S6: Most frequently reported concomitant medications (≥2% of patients) (safety population, N = 107).
Concomitant medication Number (%) of patients
Acetylsalicylic acid 9 (8.4)
Methadone 9 (8.4)
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Mean (SD) 52.7 (12.93) 63.5 (11.89) 48.3 (9.86) 48.7 (12.27) 52.5 (12.74)
<65 years, n (%) 40 (87.0) 8 (53.3) 28 (96.6) 12 (85.7) 88 (84.6)
≥65 years, n (%) 6 (13.0) 7 (46.7) 1 (3.4) 2 (14.3) 16 (15.4)
Gender, n (%)
Male 29 (63.0) 5 (33.3) 22 (75.9) 4 (28.6) 60 (57.7)
Female 17 (37.0) 10 (66.7) 7 (24.1) 10 (71.4) 44 (42.3)
BMI (kg/m2)
Mean (SD) 25.2 (6.16) 23.9 (2.92) 23.6 (4.92) 25.9 (3.73) 24.6 (5.04)
Cirrhosis status, n (%)
Non-cirrhotic 45 (97.8) 13 (86.7) 26 (89.7) 14 (100) 98 (94.2)
Cirrhotic 1 (2.2) 2 (13.3) 3 (10.3) 0 6 (5.8)
HCV pretreatment status, n (%)
Naïve 40 (87.0) 14 (93.3) 28 (96.6) 12 (85.7) 94 (90.4)
Experienced‡ 6 (13.0) 1 (6.7) 1 (3.4) 2 (14.3) 10 (9.6)
Illicit drug use, n (%)
Yes 23 (52.3) 3 (20.0) 19 (70.4) 9 (69.2) 54 (54.5)
Current 6 (13.6) 1 (6.7) 3 (11.1) 4 (30.8) 14 (14.1)
<6 months ago 1 (2.3) 0 2 (7.4) 0 3 (3.0)
6 to 12 months ago 1 (2.3) 0 0 0 1 (1.0)
>12 months ago 15 (34.1) 2 (13.3) 14 (51.9) 5 (38.5) 36 (36.4)
Mode of HCV infection, n (%)
Contaminated needle or IV drug use (current/
past)
21 (45.7) 3 (20.0) 17 (58.6) 6 (42.9) 47 (45.2)
Blood product transfusion 10 (21.7) 5 (33.3) 1 (3.4) 0 16 (15.4)
Contact with infected individual (other than verti-
cal transmission)
1 (2.2) 0 2 (6.9) 2 (14.3) 5 (4.8)
Vertical transmission (mother to child) 2 (4.3) 0 0 1 (7.1) 3 (2.9)
Occupational exposure 1 (2.2) 0 2 (6.9) 0 3 (2.9)
Unknown 11 (23.9) 7 (46.7) 7 (24.1) 5 (35.7) 30 (28.8)
Years since diagnosis of HCV infection (N = 102)
Mean (SD) 17.2 (9.56) 13.0 (10.83) 12.8 (12.03) 12.4 (8.49) 14.7 (10.47)
BMI = body mass index; GT = HCV genotype; HCV = hepatitis C virus; IV = intravenous; N = number of patients; n = number of patients with criterion; SD = standard deviation
† There were no GT5 or GT6 patients in the Swiss cohort. ‡ Includes treatment with interferon or pegylated interferon, with or without ribavirin, or sofosbuvir plus ribavirin with or
without pegylated interferon.
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